Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038974
Status:
COMPLETED
Last Update Posted:
2017-08-03
First Post:
2002-06-05
Brief Title:
Hepatitis C Antiviral Resistance in African-Americans
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Study Overview
Official Title:
Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C Virahep-C
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin Reasons for differences in response regardless of race will be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U01DK060341 | NIH | None | httpsreporternihgovquickSearchU01DK060341 |
| U01DK060329 | NIH | None | None |
| U01DK060340 | NIH | None | None |
| U01DK060324 | NIH | None | None |
| U01DK060344 | NIH | None | None |
| U01DK060327 | NIH | None | None |
| U01DK060335 | NIH | None | None |
| U01DK060352 | NIH | None | None |
| U01DK060342 | NIH | None | None |
| U01DK060345 | NIH | None | None |
| U01DK060309 | NIH | None | None |
| U01DK060346 | NIH | None | None |
| U01DK060349 | NIH | None | None |